Science & innovation investment framework, 2004-2014
- A view from the City

European Equity Strategy
Andrew Barker +44 20 7568 0468
Is the UK stock market an asset or a liability?

“The share of business R&D accounted for by small and medium sized firms…. is high in the UK compared to other major OECD economies… Analysis by the OECD suggests that R&D intensity is correlated with the size distribution of R&D performing firms. This suggests that the UK’s lower R&D intensity is, at least in part, due to lower levels of R&D amongst larger UK firms…”

Science & innovation investment framework, p. 60

“Capital markets may also provide insufficient opportunities for companies to shift risk, owing to the asymmetric information between investor and company, and the difficulty of securing finance on intangible knowledge assets.”

Science & innovation investment framework, p. 63
The UK equity market – pre-eminent in Europe

The market capitalisation of Europe: UK accounts for €1.7tr out of total €4.8tr
The innovation balance sheet: UK non-financials

**ASSETS**
- tangible fixed assets, net working capital
- investments
- market value of intangibles
  - R&D
  - A&P / brand
  - people
  - growth

**FINANCING**
- debt
- market value of equity

62%
100%
The innovation balance sheet: Honeywell (US)

<table>
<thead>
<tr>
<th>ASSETS</th>
<th>FINANCING</th>
</tr>
</thead>
<tbody>
<tr>
<td>net cash</td>
<td>100%</td>
</tr>
<tr>
<td>tangible fixed assets, net working capital</td>
<td>51%</td>
</tr>
<tr>
<td>investments</td>
<td></td>
</tr>
<tr>
<td>market value of intangibles</td>
<td></td>
</tr>
<tr>
<td>R&amp;D</td>
<td></td>
</tr>
<tr>
<td>A&amp;P / brand</td>
<td></td>
</tr>
<tr>
<td>people</td>
<td></td>
</tr>
<tr>
<td>growth</td>
<td></td>
</tr>
</tbody>
</table>

market value of equity
The innovation balance sheet: Smiths Group (UK)

**ASSETS**
- tangible fixed assets, net
- working capital
- investments
- market value of intangibles
  - R&D
  - A&P / brand
  - people
  - growth

**FINANCING**
- 82%
- 100%
- debt
- market value of equity
The value of innovation: UK vs France vs Germany

% of market capitalisation accounted for by intangible assets

(62%) UK
(56%) France
(19%) Germany

(based on non-financial companies in Eurotop 300 index, and UBS 2004 forecasts)
The time value of innovation: Smiths Group

% of today’s market value accounted for by cash flows from different future periods

(based on UBS 2004 forecasts; standard dividend discount model)
Nokia: a salutory case

In the last 5 trading days, Nokia has lost 16% of its market value, or E8.6bn

16/7/04: “We increase our R&D estimates by 22% in 3Q04, 13% in 2004 and 10% in 2005. R&D spending is tracking higher than expected, due to the desire to fund new programmes to support longer-term product development…”

UBS research note
Companies are now unusually conservative

Cash surplus (deficit), European large-capitalisation companies
Conservatism is being rewarded

2004 PE multiple of Portugal Telecom, announcement of share buy-back

<table>
<thead>
<tr>
<th>Month</th>
<th>Jul-03</th>
<th>Aug-03</th>
<th>Sep-03</th>
<th>Oct-03</th>
<th>Nov-03</th>
<th>Dec-03</th>
<th>Jan-04</th>
<th>Feb-04</th>
<th>Mar-04</th>
<th>Apr-04</th>
</tr>
</thead>
<tbody>
<tr>
<td>PE</td>
<td>12.3</td>
<td>12.2</td>
<td>12.7</td>
<td>13.5</td>
<td>14.6</td>
<td>15.8</td>
<td>17.4</td>
<td>15.4</td>
<td>16.0</td>
<td>15.6</td>
</tr>
</tbody>
</table>
Question 2

Is there any evidence in the long-term that investors gain from supporting companies in their R&D efforts?
Does science and innovation pay? (investors’ view - 1)

Methodology – creating an “R&D portfolio”

♦ We ranked all stocks in the US Russell 2000 (index of top 2000 quoted US companies) by their ratio of R&D to total assets, every month for the past 25 years: 600,000 data points

♦ We selected the top and bottom quintiles on this measure every month, and constructed a portfolio to go long of the top basket, and short of the bottom one

♦ We measured the cumulative returns to this portfolio strategy over time

♦ In other words, we have tried to isolate the total returns to an investor in the US stocks that (in each month) are spending the most on R&D. It does not represent the performance of the individual stocks from end to end: the position of the stocks in the rankings may change over time.
Does science and innovation pay? (investors’ view - 2)

How the “R&D portfolio” would have performed over the last 25 years, US Russell 1000 (larger companies)
Does science and innovation pay? (investors’ view - 3)

..substituting capital spending for R+D
Investors prefer large company R+D over small company R+D
Does science and innovation pay? (investors’ view - 5)

Results by sector are very different – the R&D-sensitive ones

[Graph showing stock performance by sector from Jan-79 to Jan-04]
Results by sector are very different – the less R&D-sensitive ones
Is the UK financial services industry an asset or a liability?

“The City of London is one of the most competitive financial services clusters in the world. The UK ranks 1 in the Global Competitiveness Report on the sophistication of its financial markets. Its equity markets in particular are rated highly…”

UK Competitiveness: moving to the next stage, (Porter and Ketels) p. 60
The UK finance industry – pre-eminent in Europe

European equity markets – location of intellectual capital

(according to UBS equity analyst location)
UK finance industry – major development spenders

UBS Investment Bank – global headcount by category

- **Client facing**: 48%, 8,269
- **IT development**: 32%, 5,438
- **Operations**: 20%, 3,455
The UK finance industry – shading out the rest?

The relative significance of stock market careers: US = 100

(according to UBS equity analyst location, market share)
One investment analyst / engineer’s career path

♦ Graduated from University of York in 1986, with BSc, electronic engineering

♦ Joined Plessey Electronics, in Electromagnetics Consulting Group, specialising in advanced electronic designs of military equipment

♦ “I decided to leave Plessey after my first annual review, when I was told that I could not achieve the next grade because the minimum age requirement was 24”

♦ Became investment analyst following electronics and industrials companies

♦ Was voted in top 3 aerospace / defence analysts in the world, 2000 and 2001, and best analyst in Europe

♦ Now UBS Managing Director and head of Telecom research team
Conclusions

♦ Question 1: The UK has a noticeably larger and more liquid stock market than those of its competitors. This market takes a long-term view, and already values science and innovation highly. It should be in a position to facilitate, rather than hinder, UK business R&D. At the moment though, market conditions around the world are hostile towards any kind of long term investment.

♦ Question 2: in the long run, the US experience suggests that equity investors should profit from a policy of favouring firms with high R&D, although this is most true for larger companies, and for certain sectors.

♦ Question 3: The UK wholesale financial services industry is highly productive, and exports successfully. It is itself, though, a major pull on the UK’s scientific / innovative talent pool: is there any way of redressing the careers imbalance?
Each research analyst primarily responsible for the content of this research report, in whole or in part, certifies that with respect to each security or issuer that the analyst covered in this report: (1) all the views expressed accurately reflect his or her personal views about those securities or issuers; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in the research report.

Global ratings: Definitions and allocations

<table>
<thead>
<tr>
<th>UBS rating</th>
<th>Definition</th>
<th>UBS rating</th>
<th>Definition</th>
<th>Rating category</th>
<th>Coverage</th>
<th>IB services</th>
</tr>
</thead>
<tbody>
<tr>
<td>Buy 1</td>
<td>Excess return potential &gt; 15%, smaller range around price target</td>
<td>Buy 2</td>
<td>Excess return potential &gt; 15%, larger range around price target</td>
<td>Buy</td>
<td>47%</td>
<td>35%</td>
</tr>
<tr>
<td>Neutral 1</td>
<td>Excess return potential between -15% and 15%, smaller range around price target</td>
<td>Neutral 2</td>
<td>Excess return potential between -15% and 15%, larger range around price target</td>
<td>Hold Neutral</td>
<td>47%</td>
<td>32%</td>
</tr>
<tr>
<td>Reduce 1</td>
<td>Excess return potential &lt; -15%, smaller range around price target</td>
<td>Reduce 2</td>
<td>Excess return potential &lt; -15%, larger range around price target</td>
<td>Sell</td>
<td>6%</td>
<td>26%</td>
</tr>
</tbody>
</table>

Excess return: Target price / current price - 1 + gross dividend yield - 12-month interest rate. The 12-month interest rate used is that of the company's country of incorporation, in the same currency as the predicted return.

This report was produced by: UBS Limited

Head office: UBS Limited, 1 Finsbury Avenue, London, EC2M 2PP, UK Phone: +44-20-7567 8000

This report has been prepared by UBS AG or an affiliate hereof ("UBS"). In certain countries UBS AG is referred to as "UBS SA".

This report is for distribution only under such circumstances as may be permitted by applicable law. It has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient. It is published solely for informational purposes and is not to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. No representation or warranty, either express or implied, is provided in relation to the accuracy, completeness or reliability of the information contained herein, except with respect to information concerning UBS AG, its subsidiaries and affiliates, nor is it intended to be a complete statement or summary of the securities, markets or developments referred to in the report. The report should not be regarded by recipients as a substitute for the exercise of their own judgement. Any opinions expressed in this report are subject to change without notice and may differ or be contrary to opinions expressed by other business areas or groups of UBS as a result of using different assumptions and criteria. UBS is under no obligation to update or keep current the information contained herein. UBS, its directors, officers and employees (including the US broker-dealer unless specifically disclosed under required disclosures) may act or have acted as market-maker in the securities or other financial instruments discussed in this report. Furthermore, UBS may have or have had a relationship with or may provide investment banking, capital markets and/or other financial services to the relevant companies. Employees of UBS may serve or have served as officers or directors of the relevant companies. UBS may rely on information barriers, such as "Chinese Walls," to control the flow of information contained in one or more areas within UBS, into other areas, units, groups or affiliates of UBS.

The securities described herein may not be suitable for sale in all jurisdictions or to certain categories of investors. Options, derivative products and futures are not suitable for all investors, and trading in these instruments is considered risky. Past performance is not necessarily indicative of future results. Foreign currency rates of exchange may adversely affect the value, price or income of any security or related instrument mentioned in this report. For investment advice, trade execution or other enquiries, clients should contact their local sales representative. Neither UBS nor any of its affiliates, nor any of UBS’ or any of its agents accepts any liability for any loss or damage arising out of the use of all or any part of this report. Additional information will be made available upon request.

United Kingdom and rest of Europe: Except as otherwise specified herein, this material is communicated by UBS Limited, a subsidiary of UBS AG, to persons who are market counterparties or intermediate customers (as detailed in the FSA Rules) and is only available to such persons. The information contained herein does not apply to, and should not be relied upon by, private customers. Switzerland: Distributed by UBS AG to persons who are institutional investors only. Italy: Should persons receiving this research in Italy require additional information or wish to effect transactions in the relevant securities, they should contact Guernica UBS SIM S.p.A., an associate of UBS SA, in Milan. South Africa: UBS Securities South Africa (Pty) Limited (incorporating J.D. Anderson & Co.) is a member of the JSE Securities Exchange South Africa, United States: Distributed to US persons by either UBS Securities LLC or UBS Financial Services Inc., subsidiaries of UBS AG, or by a group, subsidiary or affiliate of UBS AG that is not registered as a US broker-dealer (a "non-US affiliate"); UBS Securities LLC or UBS Financial Services Inc. accepts responsibility for the content of a report prepared by another non-US affiliate when distributed to US persons by UBS Securities LLC or UBS Financial Services Inc. All transactions by a US person in the securities or other financial instruments discussed in this report must be effected through UBS Securities LLC or UBS Financial Services Inc., and not through a non-US affiliate. Canada: Distributed by UBS Securities Canada Inc., a subsidiary of UBS AG and a member of the principal Canadian stock exchanges & CIPF. A statement of its financial condition and a list of its directors and senior officers will be provided upon request. Hong Kong: Distributed by UBS Securities Asia Limited, Singapore: Distributed by UBS Securities Singapore Pte. Ltd. Japan: Distributed by UBS Securities Japan Ltd to institutional investors only. Australia: Distributed by UBS Capital Markets Australia Ltd and UBS Securities Australia Ltd licensed securities dealers. New Zealand: Distributed by UBS New Zealand Ltd.

This report was produced by: UBS Limited

©2003 UBS. All rights reserved. This report may not be reproduced or redistributed, in whole or in part, without the written permission of UBS and UBS accepts no liability whatsoever for the actions of third parties in this respect.